Age-related Macular Degeneration

HMS Ophthalmology Center of ExcellenceCenter of Excellence

 
The Age-related Macular Degeneration (AMD) Center of Excellence is dedicated to unraveling the complex and multifactorial causes of AMD, the leading cause of blindness in developed countries.

Age Related Macular Degeneration

CO-DIRECTORS
Patricia A. D'Amore, PhD, MBA
Deeba Husain, MD
Ivana K. Kim, MD
MEMBERS
See a list of AMD faculty

Age-related macular degeneration (AMD) occurs in neovascular ("wet" or exudative) and nonneovascular ("dry" or nonexudative) forms, and according to the World Health Organization, it is the leading cause of blindness in developed countries and ranks third worldwide after cataract and glaucoma. Investigators in the AMD Center of Excellence made numerous groundbreaking contributions to the understanding and treatment of AMD. They pioneered the pharmacologic treatment of AMD with the development of verteporfin photodynamic therapy (Visudyne). They also identified the role of vascular endothelial growth factor (VEGF) in vascular eye disease, forming the scientific basis of current anti-VEGF therapies for neovascular AMD, diabetic macular edema, and macular edema following retinal vein occlusion (RVO). Our researchers are currently working to advance the diagnosis, prevention, and treatment of AMD; they are investigating the risk factors (genetic and environmental) that predispose individuals to the disease, and are working to define the underlying pathophysiology with a goal of developing novel approaches to diagnosis and therapy.
 

Featured Event

5th Biennial International Symposium on AMD

Fall 2018 | Boston, MA

The Biennial International Symposium on AMD brings together international experts from a diverse array of fields as well as leaders from related disciplines outside ophthalmology in an interactive format to discuss current and future topics in AMD research. Learn more...

 

Featured News

Symposium on AMD Gala Dinner at the Liberty Hotel, Boston

AMD Symposium Facilitates Open Dialogue on Innovative Research

November 3, 2016

At the fourth Biennial International Symposium on AMD, held October 21-22, 2016 in Boston, more than 200 clinicians, researchers, trainees, and industry representatives discussed current AMD topics and the challenges that lay ahead. One of the central themes of this year’s symposium was the need for a more precise stratification of the disease.

Patients with High-Risk Macular Degeneration Show Improvement with High-Dose Statin Treatment

Patients with High-Risk Macular Degeneration Show Improvement with High-Dose Statin Treatment

February 4, 2016

A phase I/II clinical trial at Massachusetts Eye and Ear found that some patients taking high doses of atorvastatin (cholesterol-lowering medication) had complete resolution of lipid deposits in the dry form of age-related macular degeneration (AMD). AMD is the leading cause of blindness in the developed world, and though effective treatments are available for the wet AMD, they are currently lacking for the more-prevalent dry form.

Eyes on the Complement System at the Third International Biennial Symposium on AMD 

October 27, 2014

Drawing nearly 250 clinicians, researchers, trainees, and industry representatives from around the world, the Third International Biennial Symposium on AMD, which was held October 24–25, 2014 and co-chaired by Chief and Chair of Ophthalmology, Joan Miller, MD, FARVO, and AMD Center of Excellence co-directors Patricia D’Amore, PhD, MBA, FARVO and Ivana Kim, MD, had special significance because it followed the 2014 António Champalimaud Vision Award, which recognized the development of antiangiogenic therapies for AMD and other retinal diseases.

200+ Scientists and Clinicians Brainstorm at the 2nd Biennial International Symposium on Age-related Macular Degeneration

September 22, 2012

On September 21-22, 2012, Harvard Ophthalmology hosted its 2nd Biennial International Symposium on age-related macular degeneration (AMD), which spurred lively discussion and debate among more than 200 clinicians, researchers, and trainees in attendance.

More